MagnaSci Ventures

MagnaSci Ventures is a venture capital investment firm based in Houston, Texas, established in 2016. The firm specializes in investing in early-stage life science companies, aiming to support innovative healthcare solutions. Since its first investment in 2017, MagnaSci Ventures has built a portfolio that includes two companies. With an estimated revenue of less than $1 million and a small team of fewer than ten employees, the firm focuses on fostering growth and development within the life sciences sector.

Cooper Collins

Founder, Chief Investment Officer and Managing Partner

Brian Dorsey

Founding Partner

4 past transactions

Dominion Aesthetic Technologies is a laser platform medical device company headquartered in San Antonio, TX, with technical labs in Orlando, FL. Its product eon FR is a non-invasive, non-contact body contouring device is FDA cleared for full abdominal fat reduction (FR). The company’s purpose is to offer the best solutions for aesthetic physicians and practitioners. In developing new products, it utilizes the knowledge of its scientific advisory committee comprised of world-renowned experts.

Blacksmith Medicines

Seed Round in 2021
Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes.

Neurana Pharmaceuticals

Series A in 2018
Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.

Forge Therapeutics

Series A in 2017
Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.